AGI.do

Products

What will AGI do for Ajmaline?

This classification denotes an antiarrhythmic agent with the molecular formula C20H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1PON08459R, chemically known as ajmalan-17,21-diol, (17r,21.alpha.)- but more generally known as ajmaline, which bears US NIH Compound Identifier 2073. Ajmaline comes in many forms, including aspartate, ethanolate, ethylphenylbarbiturate, n-oxide, and phenylbarbiturate. European Medicines Agency schedules Ajmaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12754MIG. World Health Organization schedules ajmaline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, AJMALINE remains US FDA's Preferred Term for this commodity. Ajmaline bears US NLM identifiers UMLS ID C0001888 and NCI Concept Code C83524. SMILES: OC1C23C(N(C4C3CCCC4)C)C3N4C(C1C(C3)C(C4O)CC)C2.

How AGI delivers it

Four ways AGI delivers for Ajmaline

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Ajmaline, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Ajmaline, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Ajmaline connects

measured by

  • Active Ingredient Potencymodel
  • Compound Puritymodel
  • Residual Solventmodel

Go deeper

Explore Ajmaline

Read the deeper take on agi.asView as markdown